InMed Pharmaceuticals is a global leader in the development, manufacturing, and commercialization of rare cannabinoids. With their subsidiary BayMedica, they have unparalleled cannabinoid manufacturing capabilities to serve various consumer markets, including pharmaceuticals, health, and wellness. InMed Pharmaceuticals focuses on researching, developing, and manufacturing rare cannabinoids and cannabinoid analogs for the treatment of diseases with high unmet medical needs.

They have initiated pharmaceutical programs targeting epidermolysis bullosa, glaucoma, and neurodegenerative disease. Furthermore, InMed's subsidiary, BayMedica, produces a portfolio of premium rare cannabinoids as raw ingredients for health and wellness products. These bioidentical rare cannabinoids, such as cannabichromene (CBC) and tetrahydrocannabivarin (d9-THCV), are highly pure, consistent, and free of THC.

InMed also offers a library of cannabinoid analogs that can be selectively modified to treat specific diseases. With their experienced team and successful track record, InMed Pharmaceuticals is at the forefront of rare cannabinoid manufacturing and development